Welcome to ProAxsis

ProAxsis is developing a range of products for the capture, detection and measurement of active protease biomarkers of disease.

Our rapid and easy-to-use tests incorporate patented ProteaseTags®; smart molecules which trap an active protease within a complex biological sample and enable a visual readout of its presence. A number of active protease species have been extensively validated as biomarkers of disease activity in areas such as cancer and infection, in addition to respiratory diseases such as bronchiectasis, cystic fibrosis and COPD. 

 

 

NEATstik-LFD ELISAkit

CLINICAL RESEARCH SERVICES
ACTIVITY PROFILING
TARGET VALIDATION
CLINICAL TRIAL SUPPORT 

CLINICAL/POINT OF CARE TESTS
ProteaseTags®
CROSS PLATFORM TECHNOLOGY

ProteaseTag® Immunoassays
KIT SALES
SERVICE PROVISION
DRUG DISCOVERY

SMART MOLECULE DESIGN
ProteaseTags® LIBRARY
INHIBITOR/KINETIC ANALYSIS
CUSTOM DESIGN & SYNTHESIS

News

ProAxsis CEO to present update at Bio-Europe Spring
  Dr David Ribeiro, CEO of ProAxsis, will be attending the Bio-Europe Spring meeting, taking place...
ProAxsis gains backing of Innovate UK
ProAxsis Limited (www.proaxsis.com) is further expanding its ProteaseTag® technology platform, via a p...
ProteaseTag® Active Neutrophil Elastase Immunoassay used to predict future risk of exacerbation in bronchiectasis
In a significant new study, a team at the University of Dundee has shown for the first time that sput...
ProAxsis’ ProteaseTag® NE Immunoassay highlighted at BTS 2016
ProAxsis (www.proaxsis.com) was delighted to observe that measuring active neutrophil elastase (NE) by ...
Proaxsis